
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of1 Medicine, 2 Pathology and Laboratory Medicine, and 3 Urology, and 4 Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana; 5 MedImmune Inc., Gaithersburg, Maryland; and 6 A&G Pharmaceuticals, Inc., Columbia, Maryland
Purpose: PCDGF (PC cell-derived growth factor), also called progranulin, is a Mr 88,000 glycoprotein precursor of granulin. It is a novel growth factor that stimulates cell proliferation, confers epithelial tumorigenesis, and promotes tumor invasion. Here we investigate the potential of PCDGF as a therapeutic target for prostate cancer.
Experimental Design: We studied the expression of PCDGF in invasive prostate cancer, adjacent high-grade prostatic intraepithelial neoplasia (PIN), and benign prostate tissue from 99 human prostate specimens. The level of PCDGF expression was correlated with various clinicopathological characteristics.
Results: Normal prostate tissue did not express (53/99), or expressed low levels (46/99) of PCDGF. In the 46 normal prostate specimens that expressed PCDGF, most of them had less than 10% of cells expressing PCDGF. PCDGF expression could be detected in more than 50% of cells in all specimens of PIN and invasive prostate cancer. The expression of PCDGF in normal prostate tissue was much less intense and in a smaller fraction of cells than in PIN and invasive adenocarcinoma (P < 0.0001). There was no correlation of PCDGF expression with age, Gleason score, pathological stage, status of lymph node metastasis, extraprostatic extension, perineural invasion, surgical margins, and vascular invasion.
Conclusions: Our data suggest that the induction of PCDGF expression occurs during the development of PIN. PCDGF may be a new molecular target for the treatment and prevention of prostate cancer.
This article has been cited by other articles:
![]() |
D. Tolkatchev, S. Malik, A. Vinogradova, P. Wang, Z. Chen, P. Xu, H. P.J. Bennett, A. Bateman, and F. Ni Structure dissection of human progranulin identifies well-folded granulin/epithelin modules with unique functional activities Protein Sci., April 1, 2008; 17(4): 711 - 724. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. P. Ong, Z. He, L. Kriazhev, X. Shan, R. G. E. Palfree, and A. Bateman Regulation of progranulin expression in myeloid cells Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1602 - R1612. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Kim and G. Serrero PC Cell-Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells. Clin. Cancer Res., July 15, 2006; 12(14): 4192 - 4199. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Matsumura, M. Mandai, M. Miyanishi, K. Fukuhara, T. Baba, T. Higuchi, M. Kariya, K. Takakura, and S. Fujii Oncogenic Property of Acrogranin in Human Uterine Leiomyosarcoma: Direct Evidence of Genetic Contribution in In vivo Tumorigenesis Clin. Cancer Res., March 1, 2006; 12(5): 1402 - 1411. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |